The DOI matches its Crossref record; 50 of the 53 references it cites were found in a registry or an index.
A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression
Open accessAbstract
The glutamate N-methyl-d-aspartate receptor antagonist ketamine has a rapid antidepressant effect. Despite large research efforts, ketamine’s mechanism of action in major depressive disorder (MDD) has still not been determined. In rodents, the antidepressant properties of ketamine were found to be dependent on both the α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) and the serotonin (5-HT)1B receptor. Low 5-HT 1B receptor binding in limbic brain regions is a replicated finding in MDD. In non-human primates, AMPA-dependent increase in 5-HT 1B receptor binding in the ventral striatum (VST) has been demonstrated after ketamine infusion. Thirty selective serotonin reuptake inhibitor-resistant MDD patients were recruited via advertisement and randomized to double-blind monotherapy with 0.5 mg/kg ketamine or placebo infusion. The patients were examined with the 5-HT 1B receptor selective radioligand [11 C]AZ10419369 and positron emission tomography (PET) before and 24–72 h after treatment. 5-HT 1B receptor binding did not significantly alter in patients treated with ketamine compared with placebo. An increase in 5-HT 1B receptor binding with 16.7 % (p = 0.036) was found in the hippocampus after one ketamine treatment. 5-HT 1B receptor binding in VST at baseline correlated with MDD symptom ratings (r = −0.426, p = 0.019) and with reduction of depressive symptoms with ketamine (r = −0.644, p = 0.002). In conclusion, reduction of depressive symptoms in MDD patients after ketamine treatment is correlated inversely with baseline 5-HT 1B receptor binding in VST. Further studies examining the role of 5-HT 1B receptors in the antidepressant mechanism of action of ketamine should be conducted, homing in on the 5-HT 1B receptor as an MDD treatment response marker.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 5-HT1B receptor binding in relation to ketamine treatment response. Scatter plot of baseline [11C]AZ10419369 BPND in ventral striatum (VST) vs. decrease in MADRS-short after ketamine treatment.](https://figures.cochat.ai/paper-figures/9a1bb185ba314b73b75d7cc60afda4b9/a-randomized-placebo-controlled-pet-study-of-ketamine-s-effect-on-serotonin1b-figure-2.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“PET imaging studies found that increased 5-HT 1B receptor binding was associated with ketamine response in participants with TRD and correlated with depression symptom ratings at baseline [207]”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [207]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“A significant increase in 5-HT1B receptor binding (16.7%) was observed in the hippocampus following a single ketamine treatment.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Tiger et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The PHQ-9: Validity of a brief depression severity measure
Kroenke, K., Spitzer, R. L., & Williams, J. B. W. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.016009606.x · Cited by 44,910
A Simplex Method for Function Minimization
Nelder, J. A., & Mead, R. (1965) · The Computer Journal · doi:10.1093/comjnl/7.4.308 · Cited by 28,905
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
Jenkinson, M., Beckmann, C. F., Behrens, T. E. J., Woolrich, M. W., & Smith, S. M. (2012) · NeuroImage · doi:10.1016/j.neuroimage.2011.09.015 · Cited by 11,314
(1998) · PubMed · Cited by 10,216
(1976) · Medical Entomology and Zoology · Cited by 8,899
Domingos da Silveira da Luz, A. C., Pereira Dias, G., do Nascimento Bevilaqua, M. C., Cocks, G., Gardino, P. F., Thuret, S., & Nardi, A. E. (2013) · Neuropsychobiology · doi:10.1159/000353269 · Cited by 3,995
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
Cited by
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C., Vazquez, G., & Loo, C. (2023) · eClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 172
Mechanisms of ketamine and its metabolites as antidepressants
Hess, E. M., Riggs, L. M., Michaelides, M., & Gould, T. D. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2021.114892 · Cited by 175
Ketamine: Mechanisms and Relevance to Treatment of Depression
Kim, J., Suzuki, K., Kavalali, E. T., & Monteggia, L. M. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-051322-120608 · Cited by 145
Ketamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
“Paralleling previous preclinical research, PET imaging studies found that increased 5-HT 1B receptor binding was associated with ketamine response in participants with TRD and correlated with depression symptom ratings at baseline [207].”
ResultPrice, R. B., Kissel, N., Baumeister, A., Rohac, R., Woody, M. L., Ballard, E. D., Zarate, C. A., Deakin, W., Abdallah, C. G., Feder, A., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01757-7 · Cited by 82
Self-citation
Metadata
- Authors
- Tiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J.
- Affiliations
- Region Stockholm (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Tiger, Mikael
- ORCID
- Venue
- Translational Psychiatry
- Published
- 2020-06-01
- Volume
- 10
- Issue
- 1
- Pages
- 159-159
- ISSN
- 2158-3188 (ISSN-L)
- PMC
- PMC7261801
- OpenAlex
- W3032575279
- Cited by
- 81
- References
- 53
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 11 · 2023: 19 · 2022: 18 · 2021: 10
- FWCI
- 7.05
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Translational Psychiatry (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Vetenskapsrådet (2013-09304)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine, 5-HT1B receptor, major depressive disorder, antidepressant mechanism, ventral striatum, hippocampus, rapid-acting antidepressants, treatment response biomarkers, AMPA receptors
- MeSH terms
- Depression, Major Depressive Disorder, Humans, Ketamine, Serotonin, Selective Serotonin Reuptake Inhibitors, Receptor, Serotonin, 5-HT1B, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. https://app.cochat.ai/papers/10.1038/s41398-020-0844-4
- The paper
- Tiger, M., Veldman, E. R., Ekman, C.-J., Halldin, C., Svenningsson, P., & Lundberg, J. (2020). A randomized placebo-controlled PET study of ketamine´s effect on serotonin1B receptor binding in patients with SSRI-resistant depression. Translational Psychiatry. https://doi.org/10.1038/s41398-020-0844-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.